Drug evaluation: Lymphoseek - Neoprobe's sentinel lymph node imaging agent for use in cancer patients

Area of Science:

• Oncology
• Radiopharmaceuticals
• Medical Imaging

Background:

• Accurate lymph node imaging is crucial for staging and treatment monitoring in breast cancer and melanoma.
• Current imaging techniques may have limitations in sensitivity and specificity for detecting lymph node involvement.
• Neoprobe is developing a novel imaging agent to address these challenges.

Purpose of the Study:

• To evaluate the potential of 99mTc-DTPA-mannosyl-dextran (Lymphoseek) as an imaging agent for lymph nodes.
• To assess the utility of Lymphoseek in patients undergoing treatment for breast cancer and melanoma.

Main Methods:

• Development of 99mTc-DTPA-mannosyl-dextran (Lymphoseek) by Neoprobe.
• Initiation of Phase II clinical trials in mid-2006.
• Licensing agreement with the University of California San Diego Cancer Center.

Main Results:

• Phase II trials were initiated in mid-2006, indicating progress in clinical evaluation.
• The abstract does not contain specific results from the trials, only the initiation status.

Conclusions:

• Lymphoseek shows promise as a potential diagnostic agent for lymph node imaging.
• Further clinical evaluation through Phase II trials is underway to determine its efficacy and safety.